Abstract
Hepatitis C virus (HCV) infection becomes chronic in about 85 % of individuals as demonstrated by the persistence of HCV. It is necesseray to treat acute hepatitis C infection. Interferon-α is generally used for the treatment of acute HCV infection.A 55-year-old woman with a history of fatique and icter was diagnosed as acute hepatitis C virus infection. She was treated with interferon-α 2b 3 million unite sc three times in a week and ribavirin 1000 mg daily for 6 months. Within 2 weeks of therapy, the alanine aminotransferase (ALT) had became normal. At the end of the 3 months of therapy, HCV RNA was negative and remained negative 6 months after the end of interferon treatment (sustained response).This report suggests that interferon-α 2b and ribavirin may have a role in treatment of acute hepatitis C virus infection.
Highlights
Interferon-a 2b has been shown to be effective in the treatment of acute Hepatitis C virus (HCV) infection [1]
This report suggests that interferon-a 2b and ribavirin may have a role in treatment of acute hepatitis C virus infection
We report a case of response to interferon-a 2b and ribavirin treatment for acute hepatitis C
Summary
Interferon-a 2b has been shown to be effective in the treatment of acute Hepatitis C virus (HCV) infection [1]. We report a case of response to interferon-a 2b and ribavirin treatment for acute hepatitis C. There was no history of intravenous drug usage, blood transfusions, tattoos, travel or alchol intake Her medications included local corticosteroids for dermatologic lesions and oral antidiabetics for type 2 diabetes mellitus. The patient was tested for positive for anti-HAV IgG and negative for HBsAg, anti-HBc IgM, anti-HAV IgM, antiDelta, anti-HEV IgM and anti-HEV IgG. She was positive for antibodies to HCV by third generation ELISA. At the end of the 3 months of therapy HCV RNA was negative and remained negative 6 months after the end of interferon treatment (sustained response). Interferon in combination with ribavirin was well tolerated and there were no laboratory abnormalities
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of Clinical Microbiology and Antimicrobials
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
